Favipiravir-induced cutaneous adverse reactions in patients infected with COVID-19.
Clin Exp Dermatol
; 47(3): 573-577, 2022 Mar.
Article
in English
| MEDLINE | ID: covidwho-1504590
ABSTRACT
Favipiravir (FVP) has been used for treatment of COVID-19 in many countries. We analysed the incidence of FVP-induced cutaneous adverse reactions (CARs) in patients infected with COVID-19 who were hospitalized at Bamrasnaradura Infectious Diseases Institute, a principal centre of emerging infectious disease in Thailand, and who presented with cutaneous eruption following FVP prescription. We identified five cases of FVP-induced CARs two patients with maculopapular rash, two with urticarial rash, and one with Stevens-Johnson syndrome. The median interval between FVP treatment and rash occurrence was 7 days and the mean duration of the rash was 5 days. This report highlights that FVP can induce CARs, particularly eruptions, in COVID-19-infected patients. Clinicians should be aware of this possible drug-related allergy, and it should be excluded as a cause of rash during FVP treatment of COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Pyrazines
/
Urticaria
/
Drug Eruptions
/
Amides
Type of study:
Case report
/
Observational study
Limits:
Adult
/
Female
/
Humans
/
Middle aged
/
Young adult
Language:
English
Journal:
Clin Exp Dermatol
Year:
2022
Document Type:
Article
Affiliation country:
Ced.14953
Similar
MEDLINE
...
LILACS
LIS